OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 3rd, 2022 Company Industry JurisdictionThis Option and License Agreement (the “Agreement”) is made and entered into effective as of August 10, 2020 (the “Effective Date”), by and between GigaGen, Inc., a Delaware corporation (“GigaGen”), having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080, and Kineta, Inc., a Washington corporation (“Kineta”), having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109. GigaGen and Kineta are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 3rd, 2022 Company Industry JurisdictionThis OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of June 9, 2021 (the “Effective Date”), by and between GIGAGEN, INC., a Delaware corporation (“GigaGen”), having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080, and KINETA, INC., a Washington corporation (“Kineta”), having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109. GigaGen and Kineta are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.